Enrollment closed • Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER negative • PGR negative
|
Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • sitravatinib (MGCD516)